The Anti-atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin – an Experimental Study DOI Open Access
Marianna Stasinopoulou, Nikolaos Kostomitsopoulos, Nikolaos P.E. Kadoglou

et al.

Published: May 14, 2024

Bosentan, an endothelin-receptor antagonist (ERA), has potential anti-atherosclerotic properties. We investigated the complementary effects of bosentan and atorvastatin on progression composition atherosclerotic lesions in diabetic mice. Forty-eight male apoE-/- mice were fed high-fat diet (HFD) for 14 weeks. At week 8, diabetes was induced with streptozotocin randomized into 4 groups: 1) Control/COG: no intervention. 2) ΒΟG: 100 mg/kg/day per os. 3) ATG: 20mg/kg/day os). 4) BO+ATG: Combined administration atorvastatin. The intra-plaque contents collagen, elastin, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-a (TNF-a), matrix-metalloproteinases (MMP-2,-3,-9), TIMP-1 concentrations determined. percentage lumen stenosis significantly decreased across all treated BOG: 19.5±2.2%, 12.8±4.8%, 9.1±2.7% compared to controls (24.6±4.8%, p<0.001). Both increased collagen content fibrous cap thickness versus COG (p<0.01). All intervention groups reduced relative MCP-1, MMP-3,-9, (p<0.001). Importantly, showed modest but additive latter parameters (p<0.05). Bosentan treatment diabetic, delayed atherosclerosis enhanced plaques’ stability, showing atorvastatin, which are promising cardiovascular diseases.

Language: Английский

The Anti-atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin – an Experimental Study DOI Open Access
Marianna Stasinopoulou, Nikolaos Kostomitsopoulos, Nikolaos P.E. Kadoglou

et al.

Published: May 14, 2024

Bosentan, an endothelin-receptor antagonist (ERA), has potential anti-atherosclerotic properties. We investigated the complementary effects of bosentan and atorvastatin on progression composition atherosclerotic lesions in diabetic mice. Forty-eight male apoE-/- mice were fed high-fat diet (HFD) for 14 weeks. At week 8, diabetes was induced with streptozotocin randomized into 4 groups: 1) Control/COG: no intervention. 2) ΒΟG: 100 mg/kg/day per os. 3) ATG: 20mg/kg/day os). 4) BO+ATG: Combined administration atorvastatin. The intra-plaque contents collagen, elastin, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-a (TNF-a), matrix-metalloproteinases (MMP-2,-3,-9), TIMP-1 concentrations determined. percentage lumen stenosis significantly decreased across all treated BOG: 19.5±2.2%, 12.8±4.8%, 9.1±2.7% compared to controls (24.6±4.8%, p<0.001). Both increased collagen content fibrous cap thickness versus COG (p<0.01). All intervention groups reduced relative MCP-1, MMP-3,-9, (p<0.001). Importantly, showed modest but additive latter parameters (p<0.05). Bosentan treatment diabetic, delayed atherosclerosis enhanced plaques’ stability, showing atorvastatin, which are promising cardiovascular diseases.

Language: Английский

Citations

1